title: Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
abstract: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a hereditary cancer syndrome in which affected individuals are at risk for development of cutaneous and uterine leiomyomas and an aggressive form of type II papillary kidney cancer. HLRCC is characterized by germline mutation of the tricarboxylic acid (TCA) cycle enzyme, fumarate hydratase (FH). FH-deficient kidney cancer is characterized by impaired oxidative phosphorylation and a metabolic shift to aerobic glycolysis, a form of metabolic reprogramming referred to as the Warburg effect. Increased glycolysis generates ATP needed for increased cell proliferation. In FH-deficient kidney cancer, levels of AMP-activated protein kinase (AMPK), a cellular energy sensor, are decreased resulting in diminished p53 levels, decreased expression of the iron importer, DMT1, leading to low cellular iron levels, and to enhanced fatty acid synthesis by diminishing phosphorylation of acetyl CoA carboxylase, a rate-limiting step for fatty acid synthesis. Increased fumarate and decreased iron levels in FH-deficient kidney cancer cells inactivate prolyl hydroxylases, leading to stabilization of hypoxia-inducible factor (HIF)-1α and increased expression of genes such as VEGF and glucose transporter 1 (GLUT1) to provide fuel needed for rapid growth demands. Several therapeutic approaches for targeting the metabolic basis of FH-deficient kidney cancer are under development or are being evaluated in clinical trials, including the use of agents such as metformin, which would reverse the inactivation of AMPK, approaches to inhibit glucose transport, lactate dehydrogenase A (LDHA), the antioxidant response pathway, the heme oxygenase pathway, and approaches to target the tumor vasculature and glucose transport with agents such as bevacizumab and erlotinib. These same types of metabolic shifts, to aerobic glycolysis with decreased oxidative phosphorylation, have been found in a wide variety of other cancer types. Targeting the metabolic basis of a rare cancer such as FH-deficient kidney cancer will hopefully provide insights into the development of effective forms of therapies for other, more common forms of cancer.
authors: Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. WML@nih.gov
authors: W Marston
authors: WM
authors: Linehan
authors: Tracey A
authors: TA
authors: Rouault
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D051792:Basic Helix-Loop-Helix Proteins / Q000378:metabolism; D005649:Fumarate Hydratase / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D018231:Leiomyomatosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D009386:Neoplastic Syndromes, Hereditary; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D057170:Translational Research, Biomedical; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*
chemical_list: D055372:AMP-Activated Protein Kinases; D000970:Antineoplastic Agents; D051792:Basic Helix-Loop-Helix Proteins; D005649:Fumarate Hydratase
references: Curr Opin Genet Dev. 2010 Jun;20(3):324-9
references: 20304625
references: Cell Metab. 2013 Feb 5;17(2):271-81
references: 23395173
references: Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3387-92
references: 11248088
references: Cancer Cell. 2011 Sep 13;20(3):315-27
references: 21907923
references: Am J Surg Pathol. 2013 Jan;37(1):74-80
references: 23211287
references: Science. 2001 Apr 20;292(5516):464-8
references: 11292862
references: Cancer Cell. 2011 Oct 18;20(4):524-37
references: 22014577
references: J Urol. 1995 Mar;153(3 Pt 2):907-12
references: 7853572
references: Am J Surg Pathol. 2007 Oct;31(10):1578-85
references: 17895761
references: Cancer Genet Cytogenet. 2010 Jan 1;196(1):45-55
references: 19963135
references: Cancer Cell. 2011 Oct 18;20(4):511-23
references: 22014576
references: Oncogene. 1999 Apr 8;18(14):2343-50
references: 10327054
references: Cancer Genet. 2012 Jul-Aug;205(7-8):377-90
references: 22867999
references: Nat Genet. 1997 May;16(1):68-73
references: 9140397
references: Cancer Cell. 2002 Apr;1(3):237-46
references: 12086860
references: J Urol. 2007 Jun;177(6):2074-9; discussion 2079-80
references: 17509289
references: J Nat Prod. 2012 Mar 23;75(3):459-63
references: 22280462
references: Cell Cycle. 2010 Oct 15;9(20):4183-9
references: 20953139
references: J Pathol. 2011 Sep;225(1):4-11
references: 21630274
references: Am J Hum Genet. 2003 Jul;73(1):95-106
references: 12772087
references: J Biol Chem. 2007 Feb 16;282(7):4524-4532
references: 17182618
references: PLoS One. 2012;7(10):e48032
references: 23144724
references: Cancer Cell. 2012 Mar 20;21(3):297-308
references: 22439925
references: Genes Dev. 2007 May 1;21(9):1037-49
references: 17437992
references: Org Lett. 2009 Jan 1;11(1):57-60
references: 19061394
references: Mol Cancer. 2011 Apr 13;10:37
references: 21489257
references: J Exp Med. 2012 Feb 13;209(2):211-5
references: 22330683
references: Chem Res Toxicol. 2008 Mar;21(3):705-10
references: 18251510
references: J Biol Chem. 2007 Nov 23;282(47):34219-28
references: 17726021
references: J Urol. 2005 May;173(5):1482-6
references: 15821464
references: Genes Dev. 2011 Sep 15;25(18):1895-908
references: 21937710
references: J Urol. 2001 Mar;165(3):777-81
references: 11176466
references: Mol Cancer Ther. 2009 Mar;8(3):626-35
references: 19276158
references: Science. 2001 Nov 9;294(5545):1337-40
references: 11598268
references: J Am Acad Dermatol. 2006 Oct;55(4):683-6
references: 17010749
references: Mol Cell Biol. 2009 Aug;29(15):4080-90
references: 19470762
references: Mol Cell Biol. 2005 Jan;25(1):162-71
references: 15601839
references: Am J Pathol. 2004 Jan;164(1):17-22
references: 14695314
references: Cancer Cell. 2005 Aug;8(2):143-53
references: 16098467
references: Nature. 2011 Nov 20;481(7381):385-8
references: 22101431
references: Cancer Discov. 2011 Aug;1(3):222-35
references: 22037472
references: Nat Genet. 2002 Apr;30(4):406-10
references: 11865300
references: Cell Metab. 2006 Mar;3(3):177-85
references: 16517405
references: J Med Genet. 2006 Jan;43(1):18-27
references: 15937070
references: Cancer Cell. 2002 Apr;1(3):247-55
references: 12086861
references: Nature. 2012 Sep 27;489(7417):519-25
references: 22960745
references: Nature. 2011 Aug 17;477(7363):225-8
references: 21849978
references: Toxicol Appl Pharmacol. 2010 Apr 1;244(1):21-6
references: 19560482
references: Nat Struct Mol Biol. 2007 May;14(5):420-6
references: 17417656
references: Hum Mol Genet. 2005 Aug 1;14(15):2231-9
references: 15987702
references: Am J Pathol. 2001 Sep;159(3):825-9
references: 11549574
references: Arch Biochem Biophys. 2006 Jun 1;450(1):1-8
references: 16624247
references: Cell. 2012 Mar 16;148(6):1132-44
references: 22424225
references: Cancer Cell. 2013 Feb 11;23(2):228-37
references: 23352416